Supplementary Figure 2 from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Xiaoguang Li,Xinying Yang,Yanling Liu,Nuoxi Gong,Wenbo Yao,Peizhan Chen,Jiangjiang Qin,Huizi Jin,Jingquan Li,Ruiai Chu,Lei Shan,Ruiwen Zhang,Weidong Zhang,Hui Wang

DOI: https://doi.org/10.1158/1078-0432.22451807

2023-01-01

Abstract:JA causes disruption of the mitochondrial membrane potential in Raji cells.

What problem does this paper attempt to address?

Supplementary Figure 3 from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Xiaoguang Li,Yang Xia,Yanling Liu,Nuoxi Gong,Wenbo Yao,Peizhan Chen,Jiang‐Jiang Qin,Hui‐Zi Jin,Jingquan Li,Ruiai Chu,Lei Shan,Ruiwen Zhang,Weidong Zhang,Hui Wang

DOI: https://doi.org/10.1158/1078-0432.22451804.v1

2023-01-01

Abstract:Inhibition of localized growth and dissemination to multiple organs of NAMALWA cells
Supplementary Figure Legends from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Xiaoguang Li,Yang Xia,Yanling Liu,Nuoxi Gong,Wenbo Yao,Peizhan Chen,Jiang‐Jiang Qin,Hui‐Zi Jin,Jingquan Li,Ruiai Chu,Lei Shan,Ruiwen Zhang,Weidong Zhang,Hui Wang

DOI: https://doi.org/10.1158/1078-0432.22451801

2023-01-01

Abstract:Supplementary figure legends
Cancer Therapy : Preclinical JaponiconeASuppressesGrowth of Burkitt LymphomaCells through Its Effect on NFk B

Xiaoguang Li,Xinying Yang,Yanling Liu,Nuoxi Gong,Wenbo Yao,Peizhan Chen,Jiangjiang Qin,Huizi Jin,Jing-quan Li,Rui-ai Chu,L. Shan,Ruiwen Zhang,Weidong Zhang,Hui Wang

2013-01-01

Abstract:Purpose:NF-kB, a transcriptional regulatorofdiversegenes involved in cell survival, proliferation, adhesion, and apoptosis, has been implicated in various malignancies. We discovered a potent natural NF-kB inhibitor, Japonicone A, from the traditional herb Inula japonica Thunb, evaluated its preclinical pharmacology and therapeutic activity, and investigated the underlying mechanisms of action for its antitumor activity. Experimental Design: Various types of cancer and normal cells were exposed to Japonicone A for cytotoxicity screening, followed by determination of cell apoptosis and cell-cycle arrest. Western blotting, immunostaining, and gene reporter assay were used to analyze NF-kB activity. Two xenograft models were used for therapeutic efficacy evaluation. Results: Japonicone A killed cancer cells but had low cytotoxicity to normal cells. Burkitt lymphoma cells were particularly sensitive. Japonicone A inhibited the growth and proliferation of Raji, BJAB, and NAMALWA lymphoma cells and resulted in G2–M phase arrest and apoptosis. Furthermore, exposure of cells to Japonicone A caused inactivation of the TNF-a–TAK1–IKK-NF-kB axis and inhibition of TNFa–stimulated NF-kB activity and nuclear translocation, followed by downregulation of NF-kB target genes involved in cell apoptosis (Bcl-2, Bcl-xL, XIAP, TRAF2) and in the cell cycle and growth (cyclin D, c-Myc). Moreover, Japonicone A inhibited local growth and dissemination of cancer cells tomultiple organs in vivo. Conclusion: Japonicone A exerts significant anticancer effects on Burkitt lymphoma cells in vitro and in vivo through targeting of theNF-kB signaling cascade. These results highlight thepotential of JaponiconeA as a chemotherapeutic agent and warrant its development as a therapy for lymphomas. Clin Cancer Res; 19(11); 2917–28. 2013 AACR.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
JaponiconeA Induces Apoptosis of Bortezomib-Sensitive and -Resistant Myeloma Cells in Vitro and in Vivo by Targeting IKKβ

Zilu Zhang,Chenjing Ye,Jia Liu,Wenbin Xu,Chao Wu,Qing Yu,Xiaoguang Xu,Xinyi Zeng,Huizi Jin,Yingli Wu,Hua Yan

DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0473

2021-01-01

Cancer Biology and Medicine

Abstract:Objective: Multiple myeloma (MM) remains incurable with high rates of relapse. New therapeutic drugs are therefore urgently needed to improve the prognosis. JaponiconeA (JA), a natural product isolated from Inula japonica Thunb, has shown good anti-MM potential. A comprehensive study should therefore be conducted to identify both the in vitro and in vivo mechanisms of the anti-MM effects of JA. Methods: CCK8 assays and flow cytometry were used to detect the proliferation, apoptosis, and cell cycle of MM cell lines when treated with JA. In vivo experiments were conducted using subcutaneous xenograft mouse models. We also identified possible targets and the mechanism of JA using RNA-seq and c-Map databases, and identified the specific targets of JA in bortezomib-sensitive and -resistant MM cell lines using CETSA, DARTS, and rescue experiments. Furthermore, JA and bortezomib were used separately or together to characterize their possible synergistic effects. Results: In vitro, JA inhibited proliferation, and induced apoptosis and G2/M phase arrest in MM cell lines, and selectively killed primary CD138+ MM cells. In vivo, JA also demonstrated a strong anti-tumor effect with no observable toxicity. In addition, JA showed synergetic effects in combination with bortezomib, and enhanced the anti-tumor effect of bortezomib in bortezomib-resistant cells. CETSA and DARTS confirmed direct binding of JA to NF-κB inhibitor kinase beta (IKKβ), and overexpression of IKKβ or knockdown of IκBα partially rescued the apoptosis induced by JA. Conclusions: JA exhibited strong anti-tumor effects in MM. It sensitized myeloma cells to bortezomib and overcame NF-κB-induced drug resistance by inhibiting IKKβ, providing a new treatment strategy for MM patients.
Supplementary Figure 2 from Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species

Yanli Jin,Zhongzheng Lu,Ke Ding,Juan Li,Xin Du,Chun Chen,Xiaoyong Sun,Yongbin Wu,Jing Zhou,Jingxuan Pan

DOI: https://doi.org/10.1158/0008-5472.can-09-3950

2023-01-01

Abstract:Supplementary Figure 2 from Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species
The Opposite Effects On Raji Cells Associated With Transmembrane Tnf - Alpha-Mediated Bidirectional Signaling

Hailong Zhang,Dan Yan,Xu Shi,Jing Wang,Xiaodan Jiang,Zhuoya Li

DOI: https://doi.org/10.1096/fasebj.21.5.a443-b

2007-01-01

The FASEB Journal

Abstract:The present study was designed to explore the mechanism by which Raji cell is sensitive to transmembrane tumor necrosis factor-α (tmTNF-α), but resistant to soluble TNF-α (sTNF-α). By bioassay analysis, it was found that tmTNF-α induced high cytotoxicity in Raji cells by 60%, which could be blocked by TNF-α antibody. However, sTNF-α stimulated cell proliferation. By luciferase reporter assay, we found that NF-κB in Raji cells was constitutively activated, which was completely blocked by exogenous tmTNF-α Interestingly, when NF-κB activity was inhibited by PDTC (5 μM), sTNF-α exhibited cytotoxicity rather than proliferation in Raji cells. To further determine the contribution of tmTNF-α to the constitutive activation of NF-κB, antisense oligonucleotide (AON) specific to TNF-α for gene silencing was used. It was found that TNF-α expression decreased by 50% in AON-transfected cells, which was accompanied by a decrease of NF-κB activity, thereby rendered cells sensitivity to sTNF-α induced cytotoxicity. Moreover, the transfection of Raji cells with a mutant tmTNF-α that lacks intracellular domain was shown to suppress NF-κB activation, indicating that reverse signaling via tmTNF-α is involved in NF-κB activation. These results suggest that tmTNF-α may inhibit NF-κB activation via forward signaling and thus kill Raji cells, while it may induce constitutive activation of NF-κB via reverse signaling which confers the resistance of Raji cells to sTNF-α cytotoxicity (supported by the National Natural Science Foundation of China 30471586).
Supplementary Figure 1B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Qiang Du,Xinglu Zhang,Jon Cardinal,Ziping Cao,Guo Zhang,Lei Shao,David A. Geller

DOI: https://doi.org/10.1158/0008-5472.22379928.v1

2023-01-01

Abstract:Supplementary Figure 1B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells
Inhibition of JAK2/STAT3 Signaling Pathway Suppresses Proliferation of Burkitt’s Lymphoma Raji Cells Via Cell Cycle Progression, Apoptosis, and Oxidative Stress by Modulating HSP70

Neng-Wen Xu,Yu Chen,Wei'e Liu,Yan-Jie Chen,Zhi-Min Fan,Min Liu,Lin-Jie Li

DOI: https://doi.org/10.12659/msm.910170

2018-01-01

Medical Science Monitor

Abstract:Background: The aim of this study was to investigate the effect of the JAK2/STAT3 pathway on the proliferation, cell cycle distribution, apoptosis, and oxidative stress of Raji cells via regulating HSP70 expression. Material/Methods: Raji cells were divided into Blank, HSP70 siRNA, NC siRNA, AG490 (a JAK2/STAT3 signaling pathway inhibitor), and HSP70 siRNA + rh JAK2 (recombinant human JAK2) groups. HSP70 expression was detected by quantitative real-time reverse transcription-PCR (qRT-PCR); the expression levels of HSP70 and JAK2/STAT3 pathway-related proteins were evaluated by Western blotting; cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays; cell cycle distribution was observed by flow cytometry; cell apoptosis was tested by Annexin V-FITC/PI and Hoechst 33342/PI staining; reactive oxygen species (ROS) production was measured by dichloro-dihydro-fluorescein diacetate (DCFH-DA) assays; and MDA content and SOD and GSH-Px activities were determined using detection kits. Results: AG490 obviously down-regulated HSP70 expression, inhibited proliferation, induced cell cycle arrest at the G0/G1 phase, and promoted apoptosis in Raji cells; these effects were similar to the effects of HSP70 siRNA. Furthermore, ROS production and MDA content were increased in Raji cells treated with HSP70 siRNA or AG490, while SOD and GSH-Px activities were reduced. Raji cells in the HSP70 siRNA + rh JAK2 group did not significantly differ from those in the Blank group in regards to proliferation, cell cycle, apoptosis, and oxidative stress. Conclusions: Blocking the JAK2/STAT3 signaling pathway may inhibit proliferation, induce cell cycle arrest, and promote oxidative stress and apoptosis in Raji cells via the down-regulation of HSP70.
Supplemental Material-Figure S6 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Xingjun Guo,Lei Zheng,Jianxin Jiang,Yan Zhao,Xin Wang,Ming Shen,Feng Zhu,Rui Tian,Chengjian Shi,Meng Xu,Xu Li,Feng Peng,Hang Zhang,Yechen Feng,Yu Xie,Xiaodong Xu,Wei Jia,Ruizhi He,Chencheng Xie,Jun Hu,Dawei Ye,Min Wang,Renyi Qin

DOI: https://doi.org/10.1158/1078-0432.22459139

2023-01-01

Abstract:Figure S6: IL-18 promotes proliferation and invasion of PC cells via the NF-κB pathway.
The opposite effects on Raji cells associated with transmembrane TNF‐‐α‐mediated bidirectional signaling

Hailong Zhang,Dan Yan,Xu Shi,Jing Wang,Xiaodan Jiang,Zhuoya Li

DOI: https://doi.org/10.1096/fasebj.21.5.a443-b

2007-01-01

The FASEB Journal

Abstract:The present study was designed to explore the mechanism by which Raji cell is sensitive to transmembrane tumor necrosis factor-α (tmTNF-α), but resistant to soluble TNF-α (sTNF-α). By bioassay analysis, it was found that tmTNF-α induced high cytotoxicity in Raji cells by 60%, which could be blocked by TNF-α antibody. However, sTNF-α stimulated cell proliferation. By luciferase reporter assay, we found that NF-κB in Raji cells was constitutively activated, which was completely blocked by exogenous tmTNF-α Interestingly, when NF-κB activity was inhibited by PDTC (5 μM), sTNF-α exhibited cytotoxicity rather than proliferation in Raji cells. To further determine the contribution of tmTNF-α to the constitutive activation of NF-κB, antisense oligonucleotide (AON) specific to TNF-α for gene silencing was used. It was found that TNF-α expression decreased by 50% in AON-transfected cells, which was accompanied by a decrease of NF-κB activity, thereby rendered cells sensitivity to sTNF-α induced cytotoxicity. Moreover, the transfection of Raji cells with a mutant tmTNF-α that lacks intracellular domain was shown to suppress NF-κB activation, indicating that reverse signaling via tmTNF-α is involved in NF-κB activation. These results suggest that tmTNF-α may inhibit NF-κB activation via forward signaling and thus kill Raji cells, while it may induce constitutive activation of NF-κB via reverse signaling which confers the resistance of Raji cells to sTNF-α cytotoxicity (supported by the National Natural Science Foundation of China 30471586).
Abstract 2434: the Anticancer Activity of Japonicone A is Mediated by Inhibiting NFAT1-MDM2 Pathway

Sukesh Voruganti,Jiang-Jiang Qin,Wei Wang,Ruiwen Zhang

DOI: https://doi.org/10.1158/1538-7445.am2015-2434

IF: 11.2

2015-01-01

Cancer Research

Abstract:Abstract NFAT1 plays a crucial role in cancer development and progression and has been suggested as a novel target for cancer therapy. We recently report NFAT1 promotes the expression of the MDM2 oncogene, independent of p53. The present study was designed to elucidate the mechanisms of action for a newly identified NFAT1 inhibitor, Japonicone A (JapA), and demonstrate the value of targeting NFAT1-MDM2 signaling in cancer therapy. JapA was identified as a novel NFAT1 inhibitor from our initial screening of a natural product library. Its effects on NFAT1 expression and stability were analyzed in several human breast cancer cell lines with different genetic background, including MCF-7 (estrogen receptor (ER) positive and p53 wild-type), MCF-7 p53−/− (ER positive and p53 knockout), MDA-MB-231 (triple negative and p53 mutant), and MDA-MB-468 (triple negative and p53 mutant) cell lines. The effects of JapA on NFAT1 expression were also determined in MCF-7 and MDA-MB-231 xenograft tumors in vivo. To further demonstrate the specificity of JapA in targeting NFAT1-MDM2 pathway and the importance of NFAT1-MDM2 inhibition in JapA's anticancer activity, MCF7 NFAT1 overexpression (OE) and knockdown (KD) cell lines, as well as pharmacological activators and inhibitors of NFAT1 signaling were used in this study. Our results indicated that JapA showed a significant, specific inhibition of NFAT1 in breast cancer cells in vitro and in vivo. It induced NFAT1 protein ubiquitination and proteasomal degradation, and inhibited NFAT1 nuclear translocation. JapA also disrupted the binding of NFAT1 to the MDM2 P2 promoter, leading to the inhibition of MDM2 transcription. Furthermore, the inhibition of NFAT1 and the NFAT1-MDM2 signaling are critical for JapA's anticancer activity, as shown in NFAT1 OE and KD cell lines. In conclusion, JapA represents a new class of NFAT1 inhibitor. It exerts its anticancer activity through inhibiting NFAT1 and the NFAT1-MDM2 pathway, providing evidence for the value of NFAT1 as a novel target in developing effective targeted therapy for cancers. (Supported by NIH R01 CA112029, R01 CA121211, and R01 CA186662) Citation Format: Sukesh Voruganti, Jiang-Jiang Qin, Wei Wang, Ruiwen Zhang. The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2434. doi:10.1158/1538-7445.AM2015-2434
Supplementary Figure 2B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Qiang Du,Xinglu Zhang,Jon Cardinal,Ziping Cao,Guo Zhang,Lei Shao,David A. Geller

DOI: https://doi.org/10.1158/0008-5472.22379922.v1

2023-01-01

Abstract:Supplementary Figure 2B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells
Supplementary Figure 2A from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Qiang Du,Xinglu Zhang,Jon Cardinal,Ziping Cao,Guo Zhang,Lei Shao,David A. Geller

DOI: https://doi.org/10.1158/0008-5472.22379925.v1

2023-01-01

Abstract:Supplementary Figure 2A from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells
Effects of IL-6 and AG490 on Burkitt lymphoma cell growth

Pin-hao LI,Wen-xiu YANG,Qin CHEN,Yuan-yuan PEI

DOI: https://doi.org/10.3969/j.issn.1000-4718.2016.03.008

2016-01-01

Abstract:AIM:To observe the influences of IL-6 and AG490 on the growth of Raji cell line ( Burkitt lym-phoma cell, BL).METHODS:Raji cells were cultured.IL-6, an activator of signal transducer and activator of transcrip-tion 3 (STAT3), and AG490, a specific inhibitor of STAT3 were added into the medium respectively .The expression of STAT3 and survivin at mRNA and protein levels was detected by real-time PCR and Western blot .The cell viability was measured by MTT assay .Apoptosis and cell cycle were examined by flow cytometry .RESULTS:IL-6 or AG490 affected the growth of Raji cells significantly in a dose-dependent manner (P<0.05).The mRNA expression of STAT3 and sur-vivin in Raji cells was higher in IL-6 group, and lower in the AG490 group than that in the corresponding control group . The statistical differences were found in the mRNA expression of STAT 3 and survivin among different IL-6 or AG490 groups (P<0.05).The concentration dependent relationship was also presented in IL-6 and AG490 groups by the regression a-nalysis.The results of Western blot showed that the protein levels of phosphorylated STAT 3 (p-STAT3), STAT3 and sur-vivin were increased in IL-6 group, and decreased in AG490 group.The apoptotic rate of Raji cells was gradually reduced with the increasing concentration of IL-6.The opposite results were detected in the Raji cells treated with AG 490.There was significant difference in constitute of the cell cycle between the groups treated with IL -6 or AG490 and corresponding control group.The cells at G1-phase and G1/S were significantly increased , while those at S-phase had no obvious change under treating with AG490.The cells at S-phase decreased obviously in the Raji cells treated with IL-6.CONCLUSION:IL-6 and AG490 distinctly affect the growth of Raji cells .The mechanism may be associated with the activation of STAT 3 and survivin.
Supplementary Figure 1 from Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

Qian Li,Lei Shi,Bin Gui,Wenhua Yu,Jiamu Wang,Di Zhang,Xiao Han,Zhi Yao,Yongfeng Shang

DOI: https://doi.org/10.1158/0008-5472.22388579

2023-01-01

Abstract:<p>PDF file - 57K</p>
Japonicone A Antagonizes the Activity of TNF-α by Directly Targeting This Cytokine and Selectively Disrupting Its Interaction with TNF Receptor-1.

Zhenlin Hu,Jiangjiang Qin,Huahua Zhang,Dan Wang,Yaping Hua,Jieping Ding,Lei Shan,Huizi Jin,Junping Zhang,Weidong Zhang

DOI: https://doi.org/10.1016/j.bcp.2012.08.025

IF: 6.1

2012-01-01

Biochemical Pharmacology

Abstract:Anti-TNF biologics are effective therapies for various inflammatory diseases. Unfortunately, their clinical use is associated with an increased risk of infections. Selectively inhibiting TNF receptor-1 (TNFR1)-mediated signaling while preserving TNFR2 signaling may reduce inflammation yet maintain host immune response to pathogens. However, few small molecules that selectively target the TNF/TNFR system have been discovered. In the present study, we identified Japonicone A (Jap A), a nature compound derived from Inula japonica Thunb, as a novel TNF-α antagonist, as it reduced the TNF-α-mediated cytotoxicity on L929 cells and inhibited the binding of (125)I-labeled TNF-α to L929 cell surface. Furthermore, Jap A could directly bind to TNF-α rather than TNFR1 as determined by surface plasmon resonance. More importantly, Jap A could effectively inhibit the binding of TNF-α to TNFR1, while displaying only marginal inhibitory effects on that to TNFR2. Jap A also could block TNFR1-mediated signaling as it inhibited TNF-α-induced NF-κB activation in 293 cells. In addition, Jap A suppressed TNF-α-induced expressions of adhesion molecules (ICAM-1, VCAM-1) and chemokine (MCP-1) in the endothelial cells by blocking TNF-α-triggered multiple signaling pathways. Data from in vivo experiments demonstrated that Jap A protected mice from acute hepatitis induced by TNF-α/d-galactosamine, but did not compromise host antiviral immunity in adenovirus-infected mice. These results indicate that Jap A can directly target TNF-α, selectively disrupt its interaction with TNFR1, and antagonize its pro-inflammatory activities without compromising host defense against virus, thus emphasizing the potential of Jap A as an interesting lead compound for development of new anti-inflammatory drugs.
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.

Jing Li,Andrew Volk,Jun Zhang,Joseph Cannova,Shaojun Dai,Caiqin Hao,Chenglong Hu,Jiewen Sun,Yan Xu,Wei Wei,Peter Breslin,Sucha Nand,Jianjun Chen,Ameet Kini,Jiang Zhu,Jiwang Zhang

DOI: https://doi.org/10.18632/oncotarget.14220

2017-01-01

Oncotarget

Abstract:We previously reported that autocrine TNF-alpha (TNF) is responsible for JNK pathway activation in a subset of acute myeloid leukemia (AML) patient samples, providing a survival/proliferation signaling parallel to NF-kappa B in AML stem cells (LSCs). In this study, we report that most TNF-expressing AML cells (LCs) also express another pro-inflammatory cytokine, IL1 beta, which acts in a parallel manner. TNF was produced primarily by LSCs and leukemic progenitors (LPs), whereas IL1 beta was mainly produced by partially differentiated leukemic blasts (LBs). IL1 beta also stimulates an NF-kappa B-independent pro-survival and proliferation signal through activation of the JNK pathway. We determined that co-inhibition of signaling stimulated by both TNF and IL1 beta synergizes with NF-kappa B inhibition in eliminating LSCs both ex vivo and in vivo. Our studies show that such treatments are most effective in M4/5 subtypes of AML.
Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Xiaomao Guo,Zheng Li,Jianxin Jiang,Yan Zhao,Xin Wang,Ming Shen,Feng Zhu,Rui Tian,Changcheng Shi,Meng Xu,Xu Li,Pingfa Feng,Hang Zhang,Yechen Feng,Yuan Xie,Xiaodong Xu,Jia Wang,Ruizhi He,Chencheng Xie,Jun Hu,Dawei Ye,Min Wang,Renyi Qin

DOI: https://doi.org/10.1158/1078-0432.22459142.v1

2023-01-01

Abstract:Figure S5: IL-18 promotes PC cell proliferation, invasion and metastasis.

Supplementary Figure 2 from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Supplementary Figure 3 from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Supplementary Figure Legends from Japonicone A Suppresses Growth of Burkitt Lymphoma Cells Through Its Effect on NF-κB

Cancer Therapy : Preclinical JaponiconeASuppressesGrowth of Burkitt LymphomaCells through Its Effect on NFk B

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

JaponiconeA Induces Apoptosis of Bortezomib-Sensitive and -Resistant Myeloma Cells in Vitro and in Vivo by Targeting IKKβ

Supplementary Figure 2 from Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species

The Opposite Effects On Raji Cells Associated With Transmembrane Tnf - Alpha-Mediated Bidirectional Signaling

Supplementary Figure 1B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Inhibition of JAK2/STAT3 Signaling Pathway Suppresses Proliferation of Burkitt’s Lymphoma Raji Cells Via Cell Cycle Progression, Apoptosis, and Oxidative Stress by Modulating HSP70

Supplemental Material-Figure S6 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

The opposite effects on Raji cells associated with transmembrane TNF‐‐α‐mediated bidirectional signaling

Abstract 2434: the Anticancer Activity of Japonicone A is Mediated by Inhibiting NFAT1-MDM2 Pathway

Supplementary Figure 2B from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Supplementary Figure 2A from Wnt/β-Catenin Signaling Regulates Cytokine-Induced Human Inducible Nitric Oxide Synthase Expression by Inhibiting Nuclear Factor-κB Activation in Cancer Cells

Effects of IL-6 and AG490 on Burkitt lymphoma cell growth

Supplementary Figure 1 from Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14

Japonicone A Antagonizes the Activity of TNF-α by Directly Targeting This Cytokine and Selectively Disrupting Its Interaction with TNF Receptor-1.

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer